| Name | Title | Contact Details |
|---|---|---|
Mark Ammann |
Senior Vice President, Regulatory Affairs | Profile |
Mara Gladstone Holinger |
Vice President of Regulatory Affairs | Profile |
Mustang Bio, Inc., a subsidiary of Fortress Biotech, Inc., is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient`s own immune system to eliminate cancer cells. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and out-licensing or bringing the technologies to market. Mustang has partnered with the City of Hope National Medical Center (“COH”) and Fred Hutchinson Cancer Research Center in the development of proprietary chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies across many cancers. Mustang`s lead programs are in Phase 1 clinical trials at COH: MB-101 for the treatment of brain cancer and MB-102 as a therapeutic agent in acute myeloid leukemia.
CLS Health is a multi-specialty medical group with 90+ providers providing comprehensive inpatient & outpatient care in Houston, TX
Basic Research, LLC is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Phagetech is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
We are leaders in medical plastics design, development & manufacture, with over 2,000 employees, and 20 manufacturing locations worldwide.